Dentine hypersensitivity (DH) is a problem which has challenged both researchers and clinicians and bothered patients for many years, and for which no effective treatment has yet been identified.
This review of 12 clinical trials on the efficacy of oxalates on DH, was conducted using the Cochrane methodology including only randomised controlled trials or controlled trials. The findings are summarised using a meta-analysis.
Clinical trials of agents against DH present several methodological problems, some of which are common to all clinical trials, and some of which are specific to clinical trials on anti-DH agents. Amongst the former, the authors found considerable variation in risk-of-bias, as assessed using standardised methods. Amongst the latter is the measurement of pain, which has been measured in a number of different ways, eg after tactile or thermal stimulations, using a standardised air blast, or as The meta-analysis showed that only one of the oxalate compounds (3% monohydrogen monopotassium oxalate) approached a statistically significant effect on DH. However, this conclusion is based on seven trials, of which three showed no effect, or an effect in favour of placebo, three showed marginal effect in favour of oxalate, while one trial showed a marked effect in favour of oxalate. This trial however, did not report the age of the subjects, included a small number of observations (15), and presented only patient-reported effect on routine activities.
At the end of the manuscript the authors conclude that 'available evidence suggests that oxalates are not effective in decreasing DH …'.
When assessing evidence, it is however often repeated that 'no evidence of effect' is not the same as 'evidence of no effect'. With this in mind, the last sentence in the abstract is a more appropriate summary of the findings of this review: '… available evidence currently does not support the recommendation of dentine hypersensitivity treatment with oxalates'.
